critical limb ischemia



Moovly Media Inc.
Latest Comments
image_pdfimage_print

Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement

In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas […]


Hemostemix’s stem cell therapy pursues ‘Your Fountain of Youth’

What’s a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood flow) and […]


Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy

Every year modern medicine makes new breakthroughs that continue to amaze. Today’s company has a breakthrough ‘stem cell therapy,’ designed […]


Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01)

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | […]